Can Merck/Roche hep C deal put Victrelis combo on top?

What's better than Big Pharma marketing power? Big Pharma marketing power times two. Merck has tapped Roche to help sell its new hepatitis C drug Victrelis, aiming to combat the perceived edge of soon-to-be-approved competitor Incivek from Vertex Pharmaceuticals and Johnson & Johnson.

What's interesting about this co-promotion deal is that Merck and Roche make rival hepatitis C drugs, Peg-Intron and Pegasys. They're interferon injections are part of the standard two-drug therapy for the disease. Victrelis is an add-on, creating a three-drug cocktail that's proven to be more effective at curing hep C than the standard two-drug combo and work more quickly than the standard therapy, which has its share of unpleasant side effects.

Merck will market Victrelis as an addition to the Peg-Intron cocktail, while Roche will promote its combination with Pegasys. And Pegasys has muscle; it currently owns about three-quarters of the interferon market in hepatitis C, Bloomberg says. Plus, Merck's trials for Victrelis tested the drug in combination with Peg-Intron, so having Roche put its stamp on Victrelis as a Pegasys add-on could help offset the lack of data there. That's what Sanford Bernstein's Tim Anderson figures: "Now, with Roche on board, this potential shortcoming gets more than removed, in our opinion."

Together, the two companies will be working to shoulder Incivek aside. "In essence, the Merck-Roche agreement effectively tries to shut telaprevir (Incivek) out of the market to some degree," Anderson said (as quoted by Medical Marketing & Media). The marketing deal covers the U.S. right now, but the companies said it could be expanded to other markets as well.

- here's the Merck release
- get the coverage from MM&M
- see the Bloomberg piece
- get more from The Street
- read the Reuters news

Suggested Articles

Belén Garijo, currently CEO of Merck Healthcare, will succeed Stefan Oschmann as the German company's chief exec when his tenure ends in April 2021.

More than 60 researchers and bioethicists called on Pfizer to take time to collect more COVID-19 vaccine safety data, Bloomberg reports. 

Leaked details about an ad campaign to quell coronavirus fears before the election raise "every red flag I could dream of," an ex-HHS official said.